Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Change in Acquisitions & Divestments (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Change in Acquisitions & Divestments data on record, last reported at $37.3 million in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 17.3% year-over-year to $37.3 million; the TTM value through Dec 2025 reached $159.0 million, up 1.18%, while the annual FY2025 figure was $159.0 million, 1.18% up from the prior year.
  • Change in Acquisitions & Divestments reached $37.3 million in Q4 2025 per CTNM's latest filing, up from $33.7 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $48.7 million in Q1 2025 and bottomed at $12.6 million in Q3 2023.
  • Average Change in Acquisitions & Divestments over 3 years is $32.7 million, with a median of $35.5 million recorded in 2025.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 235.53% in 2024, then dropped 20.35% in 2025.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at $31.3 million in 2023, then skyrocketed by 44.03% to $45.1 million in 2024, then fell by 17.3% to $37.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $37.3 million in Q4 2025, $33.7 million in Q3 2025, and $39.4 million in Q2 2025.